Table 3.
Familial AD Causative Mutations for CAA
| Gene | Mutation∗ | CAA† | Notes‡ | References§ |
|---|---|---|---|---|
| APP | LysMet670/671AsnLeu | Yes | Mouse model, CAA at 12–19 months | 106 |
| Ala673Val | Yes | 107 | ||
| Asp678His | Yes | Also present with cerebral microvasculopathy (23931937) | 108 | |
| Ala692Gly | Yes | 109 | ||
| Glu693Gly | Yes | Mouse model shows no CAA | 106 | |
| Glu693Lys | Yes | 110 | ||
| Glu693Gln | Yes | Mouse model, CAA at 12–22 months | 111 | |
| Asp694Asn | Yes | Mouse model: APPSwDI (Swedish Lys760Asn/Met671Leu, Dutch Glu693Gln and Iowa Asp694Asn), considered to be the optimal CAA model | 112 | |
| Ala713Thr | Yes | WM changes, cerebral microangiopathy and CAA‖ | 113,154 | |
| Thr714Ile | Yes | Transgenic APP695 mouse harboring Lys670Asn, Met671Leu, and Thr714Ile, develops CAA | 114 | |
| Ile716Phe | Yes | 106 | ||
| Val717Phe | Yes | Mouse model shows no CAA | 115 | |
| Val717Gly | Yes | 116 | ||
| Val717Ile | Yes | Mouse model, CAA at 15 months | 117 | |
| Val717Leu | Yes | 118 | ||
| PSEN1 | Ile83_MetM84del | Yes | (DelIleMet, ΔIle83/Met84, ΔIle83/ΔMet84) | 119 |
| Met84Thr | Yes | 120 | ||
| Val89Leu (G>T) | Yes | 121 | ||
| Leu113_Ile114insThr | Yes | (Intron4, p.113+1delGly, splice5, InsThrAlaCys) | 122 | |
| Leu113Glns | Yes | 123 | ||
| Thr116Asn | Yes | 124 | ||
| Pro117Leu | Yes | 56 | ||
| Glu120Gly | Yes | 125 | ||
| Asn135Tyr | Yes | 126 | ||
| Met139Val | Yes | 127 | ||
| Ile143Met | Yes | CAA prominent in meningeal vessels | 47 | |
| Ile143Val | Yes | 128 | ||
| Leu174Met | Yes | 129 | ||
| Glu184Asp | Yes | 130 | ||
| Ile202Phe | Yes | 131 | ||
| Gly217Asp | Yes | 132 | ||
| Leu219Pro | Yes | 133 | ||
| Aal260Gly¶ | ? | 134 | ||
| Val261Phe | Yes | 135 | ||
| Gly266Ser | Yes | 136 | ||
| Pro267Ala | Yes | 137 | ||
| Leu268Pro | Yes | 138 | ||
| Arg269His | Yes | 139 | ||
| Leu271Val | Yes | 140 | ||
| Val272Ala | Yes | 141 | ||
| Arg278Ile | Yes | 127 | ||
| Glu280Ala | Yes | Paisa mutation | 142 | |
| GluE280Gly | Yes | 143 | ||
| Leu282Val | Yes | 144 | ||
| Pro284Leu | Yes | 145 | ||
| Leu286Pro | Yes | 138 | ||
| Ser290Cys | Yes | Thr291_Ser319del (ΔAla9, Δ9) | 146 | |
| Gly378Glu | Yes | 123 | ||
| Leu392Val | Yes | 145 | ||
| Asn405Ser | Yes | 147 | ||
| Gly417Ser | Yes | 148 | ||
| Ala431Val | Yes | 145 | ||
| Thr440del | Yes | 149 | ||
| PSEN2 | Aal85Val | Yes | 150 | |
| Lys115Glufs | Yes | 151 | ||
| Asn141Ile | Yes | Volga German mutation | 152 | |
| Leu221Thr | Yes | 153 |
AD, Alzheimer disease; APP, amyloid precursor protein; CAA, cerebral amyloid angiopathy; PSEN1, presenilin 1; PSEN2, presenilin 2; WM, white matter.
Genotypes of different mutations per original references derived from the Alzforum Database (http://www.alzforum.org/mutations, last accessed January 15, 2021).
Presence of variable degrees of CAA predominantly in cortical regions.
Presence or absence of CAA in various transgenic mouse models and features noted in case reports.
References include citations of four abstracts.
Magnetic resonance imaging positive for microbleeds suggests likely CAA (compare Figure 1B, images 5 and 6).
First case in Argentina with APP Ala171Thr mutation showing marked vascular pathology.154